relevance of the ipss-r during sct in patients with mds in the molecular classification era
Published 1 year ago • 30 plays • Length 3:31Download video MP4
Download video MP3
Similar videos
-
6:04
relevance of ipss-r for risk stratification in patients with mds who undergo sct
-
2:23
benefits, applicability & uses of the ipss-m in mds
-
1:39
ipss-r vs ipss-m for mds
-
2:01
updates in mds diagnosis and prognosis with the ipss-m: personalized medicine in 2023
-
3:35
real-world validation of the value of the ipss-m for prognostication in patients with mds
-
1:30
the prognostic value of patient-reported outcomes in mds
-
1:45
evaluating ipss-r and ipss-m in patients with hr-mds enrolled in stimulus-mds1 and stimulus-mds2
-
2:31
emerging treatment options for patients with esa-refractory mds: luspatercept & imetelstat
-
21:38
drawing the line: the rationale behind blood tube collection order
-
5:00
long-term results of the phase ii revive study evaluating rusfertide in patients with pv
-
1:26
incidence and risk factors associated with vod/sos in younger vs older adults after sct
-
1:14
how the ipss-m score helps personalizing treatment & combination therapies in hr-mds
-
4:31
labmt: impact of treatment prior to allogenic hct in mds
-
1:05
using whole genome sequencing to identify novel predictors for sct in patients with mds
-
3:26
the risk of thrombotic events in patients with mgus: an analysis from the istopmm trial
-
3:10
the role of ngs in mds diagnosis
-
1:16
state of the art: mds
-
4:48
the evolution of allosct in richter's transformation and its combination with biological agents
-
3:22
performance of the aipss-mds ml model in predicting os & leukemic transformation in cmml
-
1:41
novel therapies for high-risk mds
-
2:33
what can artificial intelligence bring to the diagnosis and management of mds?
-
3:38
a new set of treatment options for low-risk mds